Skip to main content

Advertisement

Table 1 Summary of trials included in the metaanalysis

From: Tumor necrosis factor alpha drugs in rheumatoid arthritis: systematic review and metaanalysis of efficacy and safety

Trial (reference) Comparisons Jadad's scale (J) Groups and N of patients Mean age (years) Mean disease duration (years) N of swollen joints N of tender joints CRP (mg/dl) HAQ Mean N of previous DMARDs Previous response to MTX
Lipsky et al. (19) Infliximab+MTX vs. MTX J [5] 3 mg/Kg 8 wk * 86 54 10 22 32 3.9 1.8 3.8 Insufficient
  3 mg/Kg 4 wk 86 52 9 21 31 3.5 1.7 2.6  
  10 mg/Kg 8 wk 87 54 11 23 32 3.3 1.7 2.5  
  10 mg/Kg 4 wk 81 52 12 24 34 4.2 1.7 2.5  
  MTX 88 51 11 21 31 4.0 1.7 2.5  
  total 428         
St. Clair et al. (20) Infliximab+MTX vs. MTX J [3] 3 mg/Kg 8 wk * 373 51 0,8 21 32 2.9 1,5 71% Not previously MTX
  6 mg/Kg 8 wk 378 50 0,9 22 33 3.0 1,5 68%  
  MTX 298 50 0,9 22 34 2.6 1,5 65%  
  total 1049        DMARDs naive  
Quinn et al. (22) Infliximab+MTX vs. MTX J [3] 3 mg/Kg 8 wk * 10 51 0,6 NA NA 4.7 1,3 Not previously DMARDs Not previously MTX
  MTX 10 53 0,5    3.7 1.3   
  total 20         
Westhovens et al. (23) Infliximab+MTX vs. MTX J [4] 3 mg/Kg 8 wk * 360 53 7.8 15 22 1.6 1.5 NA Insufficient
  10 mg/Kg 8 wk * 361 52 6.3 15 22 1.6 1.5   
  MTX 363 52 8.4 15 22 1.2 1.5   
  total 1084         
Moreland et al. (24) Etanercept vs. placebo J [5] 25 mg twice weekly * 78   11 25 33 4.7 1.6 3.3 Insufficient
  10 mg twice weekly 76 53 13 25 34 5.3 1.7 3.4  
  placebo 80 53 12 25 35 4.1 1.7 3.0  
  total 234 51        
Weinblatt et al. (25) Etanercept+MTX vs. MTX J [3] 25 mg twice weekly * 59   13 20 28 2.2 1.5 2.7 Insufficient
  MTX 30   13 17 28 2.6 1.5 2.8  
  total 89 48        
    53        
Bathon et al. (26) Etanercept vs. MTX J [2] 25 mg twice weekly * 207 51 1 24 31 3.3 NA 0.5 Not previously MTX
  10 mg twice weekly 208 50 0.9 24 31 4.4   0.5  
  MTX 217 49 1 24 30 3.7   0.6  
  total 632         
van der Heijde et al. (28) (TEMPO) Etanercept+MTX vs. MTX vs. Etanercept J [4] 25 mg twice weekly +MTX * 231   7 22 34 2.9 NA 2.3  
  25 mg twice weekly * 223   6 23 35 2.2   2.3  
  MTX 228 52 7 22 33 3.5   2.3  
  total 682 53        
    53        
Weinblatt et al. (29) (ARMADA) Adalimumab+MT X vs. MTX J [3] 40 mg/2 wk * 67 57 12 17 28 2.1 1.5 2.9 Insufficient
  20 mg/2 wk 69 53 13 17 28 2.8 1.5 3.0  
  80 mg/2 wk 73 55 12 17 30 2.8 1.5 3.1  
  MTX 62 56 11 16 28 3.1 1.6 3.0  
  total 271         
van de Putte et al. (30) Adalimumab vs. Placebo J [5] 40 mg/2 wk * 113 52 10 20 33 5.2 1.8 3.8 Insufficient
  20 mg/2 wk 106 53 9 19 33 5.2 1.8 3.7  
  20 mg/wk 112 54 11 19 35 4.7 1.8 3.6  
  40 mg/wk 103 51 11 19 33 4.9 1.8 3.8  
  Placebo 110 53 11 19 35 5.7 1.8 3.6  
  total 544         
Furst et al. (31) (STAR) Adalimumab+ DMARD vs. DMARD J [3] 40 mg/2 wk * 318   9 20 27 1.5 1.3 57–60% Insufficient
  DMARD 318   11 21 27 1.5 1.4 2 or plus  
  total 636 55        
    55        
Keystone et al. (32) Adalimumab+MT X vs. MTX J [3] 40 mg/2 wk * 207 56 11 19 27 1.8 1.4 2.4 Insufficient
  20 mg/wk 212 57 11 19 27 1.4 1.4 2.4  
  MTX 200 56 10 19 28 1.8 1.4 2.4  
  total 619         
Breedveld et al. (33) (PREMIER) Adalimumab+MT X vs. MTX vs. Adalimumab J [4] 40 mg/2 wk + MTX * 268 52 0,7 21 31 NA 1.5 NA Not previously MTX
  40 mg/2 wk 274 52 0,7 22 32   1.6   
  MTX 257 52 0,8 22 32   1.5   
  total 799         
  1. *groups receiving doses currently recommended
  2. NA: not available
  3. CRP: C-reactive protein
  4. HAQ: health assessment questionnaire